'Undetectable equals untransmittable' holds promise for a decrease in stigma, but awareness and acceptability of the message tends to still be limited to the HIV community.
While many celebrated the FDA approval of Descovy for PrEP earlier this month, advocates wonder whether it will make biomedical HIV prevention more or less accessible to those most in need.
Elizabeth Warren's newly released plan for LGBTQ Americans proves she gets the epidemic on a level beyond just medical and personal.
But the process may take months, pending Congressional approval.
Personal injury lawsuit ads targeting social media have become daily sightings. But are they doing more harm than good?
But is the U.S. ready to embrace it?
NIAID's Carl Dieffenbach, Ph.D., joins Anne Rancourt to discuss some key takeaways from the 10th International AIDS Society Conference on HIV Science.
Our new "Eyes on the End" series kicks off with an up-close-and-personal glimpse at what's driving the HIV epidemic in the Atlanta metropolitan area.
"This isn't about you," Rep. Alexandria Ocasio-Cortez (D-NY) told Gilead CEO Daniel O'Day. "We have legislated a system that allows [this] to happen."
Activists say this relatively small giveaway won't advance PrEP access or help end HIV in the U.S. the way a true price reduction would.